Andrea Deloach
Family · Waycross, GANPI 1114007044
Payments from drug & device makers
Across 71 payments — averaging $19.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$298
- Boston Scientific$228
- Abbott$107
- Pfizer$95
- Amgen$92
- Astellas Pharma US Inc$79
- plus $473 from 16 others
What the payments were for
- Food & beverage$1,372100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 18 | $298 |
| Boston Scientific | 10 | $228 |
| Abbott | 4 | $107 |
| Pfizer | 4 | $95 |
| Amgen | 5 | $92 |
| Astellas Pharma US Inc | 4 | $79 |
| Novartis | 4 | $75 |
| AbbVie | 4 | $60 |
| Boehringer Ingelheim | 3 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Corium, LLC | 1 | $33 |
| Lilly USA, LLC | 2 | $30 |
| Otsuka America Pharmaceutical, Inc. | 1 | $29 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| AstraZeneca | 1 | $25 |
| Baxter Healthcare | 1 | $24 |
| GSK | 1 | $19 |
| Bayer | 1 | $17 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
| Xeris Pharmaceuticals, Inc. | 1 | $11 |
How this compares
$1,372 in reported general payments places this provider in the 70th percentile of 6,258 family providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 83 | $65,151 |
| JardianceEmpagliflozin | 50 | $61,615 |
| TrulicityDulaglutide | 48 | $55,839 |
| OzempicSemaglutide | 46 | $50,531 |
| MounjaroTirzepatide | 43 | $45,192 |
| JanuviaSitagliptin Phosphate | 59 | $44,172 |
| XareltoRivaroxaban | 15 | $16,355 |
| JanumetSitagliptin Phos/Metformin Hcl | 18 | $10,804 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $10,646 |
| LinzessLinaclotide | 13 | $10,371 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $9,016 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,486 |
| FarxigaDapagliflozin Propanediol | 13 | $7,427 |
| BelsomraSuvorexant | 14 | $7,013 |
| SynthroidLevothyroxine Sodium | 55 | $4,033 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $30 | $101,03091 claims |
| PfizerEliquis | $95 | $65,15183 claims |
| Boehringer IngelheimJardiance | $42 | $61,61550 claims |
| Novo NordiskOzempic | $298 | $50,53146 claims |
| AbbVieLinzess, Synthroid | $60 | $14,40568 claims |
| GSKTrelegy Ellipta | $19 | $8,48613 claims |
| AstraZenecaFarxiga | $25 | $7,42713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,258 family providers in Georgia.
Other family in Waycross
- Hannah BanachWaycross$85K
- Tiffany HarkleroadWaycross$16K
- Morgan EldridgeWaycross$15K
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Morgan GroothandEvans$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.